Chief Accounting Officer Michael R Megna sold 50,490 shares for $1,962,781.45; post-transaction holdings fall to 27,046 shares (-65.1%)
Michael R Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc (KNSA), executed 2 separate sales on 2025-10-20, disposing of 50,490 shares for a blended average price of $38.87, reducing his equity position from 77,536 shares to 27,046 shares. This represents a material reduction in holdings, with pre-transaction equity stakes cut by 65.1%, while the company trades at $38.90, just 0.2% below its 52-week high. The sales come despite the company posting strong recent metrics: quarterly revenue of $156,797,000.00, net income of $17,832,000.00, and annual revenue growth of 56.6% year-over-year. However, the company remains unprofitable on a full-year basis, and the stock has appreciated 7.8% in the past 30 days and 44.6% over 90 days, creating context for the magnitude of the equity reduction. For the Chief Accounting Officer to liquidate two-thirds of a significant equity stake at elevated price levels merits investor attention to the CFO's forward-looking assessment of valuation and capital needs.